We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MCO:NYSEMoody's Corporation Analysis

Data as of 2026-07-13 - not real-time

$493.31

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Moody's shares are trading at $493.31, comfortably above the 20‑day ($466.18), 50‑day ($455.57) and 200‑day ($471.09) moving averages, with a bullish MACD (+$3.31 histogram) and an RSI of 64, suggesting short‑term momentum remains intact. However, the stock commands a **price‑to‑earnings multiple of 35.4**, more than double the industry average of 17.7, and a price‑to‑book of 28.8, while the discounted cash‑flow model pins a fair value near $205, implying a substantial valuation gap.
Fundamentally, Moody's delivers strong profitability – 74% gross margin, 45.7% operating margin and a 31.7% net margin – and an eye‑popping ROE of 71%, driven by high leverage (debt‑to‑equity 235x) and solid cash generation (free cash flow $2.27 bn). The dividend is modest at 0.85% with a low 27.6% payout, indicating sustainability. Volatility is elevated (30‑day ≈30%) and trading volume has slipped sharply, raising liquidity concerns, while beta of ~0.6 points to limited market‑wide price swings. Recent analyst consensus remains positive (median target $532.5, ~8% upside) and the company’s inclusion in Russell value indices may broaden institutional demand.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above key moving averages and bullish MACD
  • RSI still in comfortable range (64)
  • Analyst price targets indicating ~8% upside

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong profit margins and cash flow supporting dividend
  • High leverage and valuation compression risk
  • Potential institutional inflow from Russell value index inclusion

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • DCF fair value far below current price suggests downside risk
  • Sustainable earnings but valuation remains stretched
  • Regulatory environment and credit‑rating business stability

Key Metrics & Analysis

Financial Health

Revenue Growth8.10%
Profit Margin31.69%
P/E Ratio35.4
ROE71.36%
ROA14.82%
Debt/Equity235.54
P/B Ratio28.8
Op. Cash Flow$3.1B
Free Cash Flow$2.3B
Industry P/E17.7

Technical Analysis

TrendNeutral
RSI64.4
Support$437.51
Resistance$504.91
MA 20$466.18
MA 50$455.57
MA 200$471.09
MACDBullish
VolumeDecreasing
Fear & Greed Index92.16

Valuation

Fair Value$205.41
Target Price$539.90
Upside/Downside9.44%
GradeOvervalued
TypeBlend
Dividend Yield0.85%

Risk Assessment

Beta0.60
Volatility29.97%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.